A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy

Inclusion Criteria: * Part 1: have a diagnosis of metastatic or recurrent cancer and previously received anti PD1 immunotherapy provided that they received therapy up to 1 month prior to enrollment * Part 1: be willing to engage in follow-up telephone calls with a research staff * Part 1: have telephone access so they can be contacted by the research staff * Part 1: hemoglobin level of \>= 8 g/dL within 2 weeks of enrollment \* Packed red blood cell (PRBC) transfusions will be allowed to patients with hemoglobin \< 8 g/dl * Part 1: be able to understand the description of the study and give written informed consent * Part 1: able to read, write and speak English * Part 2: have a diagnosis of metastatic or recurrent cancer and previously received anti PD1 immunotherapy provided that they received therapy up to 1 month prior to enrollment * Part 2: be willing to engage in follow-up telephone calls with a research staff * Part 2: have telephone access so they can be contacted by the research staff * Part 2: have a hemoglobin level of \>=8 g/dL within 2 weeks of enrollment \* PRBC transfusions will be allowed to patients with hemoglobin \< 8 g/dl * Part 2: be able to understand the description of the study and give written or verbal informed consent * Part 2: able to read, write and speak English * Part 2: presence of fatigue as defined FACIT-F subscale of =\< 34 on a 0 to 52 scale (in which 52 = no fatigue and 0 = worst possible fatigue) * Part 2: not currently taking met…